{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:24:17Z","timestamp":1793384657119,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.juro.2009.07.018","type":"journal-article","created":{"date-parts":[[2009,9,17]],"date-time":"2009-09-17T09:05:20Z","timestamp":1253178320000},"page":"2112-2122","source":"Crossref","is-referenced-by-count":29,"title":["A Framework for the Identification of Men at Increased Risk for Prostate Cancer"],"prefix":"10.1097","volume":"182","author":[{"given":"Monique J.","family":"Roobol","sequence":"first","affiliation":[{"name":"Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz H.","family":"Schr\u00f6der","sequence":"additional","affiliation":[{"name":"Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. David","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology, University of Colorado Health Sciences Center, Denver, Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[{"name":"Department of Surgery, Durham VA Medical Center and the Departments of Surgery and Pathology, Division of Urologic Surgery, Duke Prostate Center, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Oliver","family":"Sartor","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Urology, Tulane Medical School, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[{"name":"University Health Network, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald L.","family":"Andriole","sequence":"additional","affiliation":[{"name":"Division of Urologic Surgery, Washington University in St. Louis, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2009.07.018_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/jama.294.1.66","article-title":"Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng\/ml or lower","volume":"294","author":"Thompson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.07.018_bib2","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(94)90405-7","article-title":"Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer","volume":"344","author":"Stenman","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2009.07.018_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.273.4.289","article-title":"A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer","volume":"273","author":"Gann","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.07.018_bib4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/jnci\/djj410","article-title":"Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability","volume":"98","author":"Carter","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.07.018_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2009.07.018_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0090-4295(01)01304-8","article-title":"Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging","volume":"58","author":"Fang","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.07.018_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.ju.0000132133.10470.bb","article-title":"Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study","volume":"172","author":"Antenor","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.urology.2005.08.040","article-title":"Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old","volume":"67","author":"Loeb","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.07.018_bib9","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1001\/archinte.165.16.1857","article-title":"Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study","volume":"165","author":"Aus","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.juro.2009.07.018_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.juro.2008.09.012","article-title":"Defining increased future risk for prostate cancer: evidence from a population based screening cohort","volume":"181","author":"Schroder","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.07.018_bib12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1097\/01.ju.0000127731.56103.50","article-title":"Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng\/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness","volume":"171","author":"Raaijmakers","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJMoa075819","article-title":"Cumulative association of five genetic variants with prostate cancer","volume":"358","author":"Zheng","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2009.07.018_bib14","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2005.04.015","article-title":"Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng\/ml: systematic review and meta-analysis","volume":"48","author":"Roddam","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0022-5347(05)63932-8","article-title":"Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer","volume":"169","author":"Karazanashvili","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1200\/JCO.2007.13.1490","volume":"26","author":"Ulmert","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2009.07.018_bib17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.07.018_bib18","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jnci\/djm171","article-title":"Is prostate-specific antigen velocity useful in early detection of prostate cancer?","volume":"99","author":"Etzioni","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2009.07.018_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2008.05.022","article-title":"The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review","volume":"54","author":"Schr\u00f6der","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib20","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/cncr.20408","article-title":"Human prostate cancer risk factors","volume":"101","author":"Bostwick","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2009.07.018_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3816\/CGC.2004.n.004","article-title":"Does finasteride alter the pathology of the prostate and cancer grading?","volume":"2","author":"Bostwick","year":"2004","journal-title":"Clin Prostate Cancer"},{"key":"10.1016\/j.juro.2009.07.018_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.urology.2007.06.1105","article-title":"Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng\/ml","volume":"70","author":"Canby-Hagino","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.07.018_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.20352","article-title":"A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng\/ml (results of ERSPC, Rotterdam)","volume":"66","author":"Roobol","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2009.07.018_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.urology.2007.05.017","article-title":"High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates","volume":"70","author":"Sajadi","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.07.018_bib25","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.ejca.2007.09.022","article-title":"Prostate volume and adverse prostate cancer features: fact not artifact","volume":"43","author":"Briganti","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2009.07.018_bib26","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0022-5347(05)65652-2","article-title":"Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?","volume":"166","author":"Djavan","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib27","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/01.ju.0000139320.78673.2a","article-title":"Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib28","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ijc.22427","article-title":"Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy","volume":"120","author":"Steuber","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2009.07.018_bib29","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.07.018_bib30","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.urology.2007.12.008","article-title":"Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program","volume":"71","author":"Eggener","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.juro.2009.07.018_bib31","first-page":"3323","article-title":"Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease","volume":"52","author":"Carter","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2009.07.018_bib32","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.eururo.2008.01.037","article-title":"(I) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng\/ml","volume":"53","author":"Roobol","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib33","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.eururo.2008.01.038","article-title":"(II) Re: prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng\/ml","volume":"53","author":"Roobol","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eururo.2008.01.034","article-title":"Serum markers for prostate cancer: a rational approach to the literature","volume":"54","author":"Steuber","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib35","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1373\/clinchem.2008.110668","article-title":"Emerging biomarkers for the diagnosis and prognosis of prostate cancer","volume":"54","author":"Sardana","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.juro.2009.07.018_bib36","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1055-9965.EPI-08-0556","article-title":"The role of the BRCA2 gene in susceptibility to prostate cancer revisited","volume":"17","author":"Ostrander","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.juro.2009.07.018_bib37","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/modpathol.3800053","article-title":"High-grade prostatic intraepithelial neoplasia","volume":"17","author":"Bostwick","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1016\/j.juro.2009.07.018_bib38","doi-asserted-by":"crossref","first-page":"952","DOI":"10.5858\/2006-130-952-ASAPIT","article-title":"Atypical small acinar proliferation in the prostate: clinical significance in 2006","volume":"130","author":"Bostwick","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.juro.2009.07.018_bib39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/01.mou.0000193389.31727.9b","article-title":"What's new in prostate cancer disease assessment in 2006?","volume":"16","author":"Epstein","year":"2006","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0022-5347(05)00337-X","article-title":"Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care","volume":"175","author":"Epstein","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.juro.2009.07.018_bib42","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/ijc.22956","article-title":"The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy","volume":"121","author":"Vickers","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2009.07.018_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.eururo.2008.03.079","article-title":"Digital rectal examination and the diagnosis of prostate cancer\u2014a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam","volume":"55","author":"Gosselaar","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01.ju.0000165568.76908.5c","article-title":"4-Year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam","volume":"174","author":"Schroder","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.07.018_bib45","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1001\/jama.289.20.2695","article-title":"Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations","volume":"289","author":"Eastham","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2009.07.018_bib46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00345-007-0146-y","article-title":"Role of nomograms for prostate cancer in 2007","volume":"25","author":"Chun","year":"2007","journal-title":"World J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S002253470901742X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S002253470901742X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2009.07.018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:50:34Z","timestamp":1651197034000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2009.07.018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1016\/j.juro.2009.07.018"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2009.07.018","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}